Real-world effectiveness of everolimus-based therapy versus fulvestrant monotherapy in HR(+)/HER2(-) metastatic breast cancer.
OBJECTIVE
Assessing real-world effectiveness of everolimus-based therapy (EVE) versus fulvestrant monotherapy (FUL) among postmenopausal women with hormone receptor-positive (HR(+))/HER2(-) metastatic breast cancer (mBC) after progression on nonsteroidal aromatase inhibitor (NSAI).


METHODS
Medical charts of community-based patients who received EVE or FUL for mBC after NSAI were examined. Progression-free survival (PFS), time on treatment and time to chemotherapy were compared using Kaplan-Meier curves and Cox proportional hazards models adjusting for line of therapy and patient characteristics.


CONCLUSIONS
192 patients received EVE and 156 FUL. After adjusting for patient characteristics, EVE was associated with significantly longer PFS than FUL (hazard ratio: 0.71; p = 0.045). EVE was associated with better PFS than FUL among NSAI-refractory postmenopausal HR(+)/HER2(-) mBC patients.
Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.
Yanni
Y
Hao
Analysis Group, Inc., Boston, MA 02199, USA.
Peggy L
PL
Lin
Analysis Group, Inc., New York, NY 10020, USA.
Jipan
J
Xie
Analysis Group, Inc., Boston, MA 02199, USA.
Nanxin
N
Li
Analysis Group, Inc., Boston, MA 02199, USA.
Valerie
V
Koo
Analysis Group, Inc., Boston, MA 02199, USA.
Erika
E
Ohashi
Analysis Group, Inc., Boston, MA 02199, USA.
Eric Q
EQ
Wu
Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.
Jaqueline
J
Rogerio
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D018572:Disease-Free Survival; D004958:Estradiol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000068338:Everolimus / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D000077267:Fulvestrant; D006801:Humans; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D016016:Proportional Hazards Models; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D000077267:Fulvestrant; D004958:Estradiol; D000068338:Everolimus
HR+/HER2- metastatic breast cancer; breast cancer; clinical outcomes; comparative effectiveness; endocrine therapy; everolimus; fulvestrant; postmenopausal; real-world effectiveness